|
Dec 23 |
PDS Biotech Reports An Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)...
FLORHAM PARK, N.J., Dec. 23, 2021 (GLOBE... |
|
Dec 06 |
PDS Biotech Provides Recruitment update for National Cancer Institute-Led Phase 2 Clinical Trial of PDS0101-Based Combin...
Institutional Review Board (IRB) approval has... |
|
Nov 10 |
PDS Biotech Provides Business Update and Reports Third Quarter 2021 Financial Results...
FLORHAM PARK, N.J., Nov. 10, 2021 (GLOBE... |
|
Nov 08 |
PDS Biotechnology Licenses Protein for the Treatment of Acute Myeloid Leukemia, Prostate and Breast Cancers from Nationa...
Advances Next Phase of Versamune® Oncology... |
|
Nov 01 |
PDS Biotech Announces Agreement with University of Georgia to License Novel Proteins for Versamune-based Universal Flu V...
FLORHAM PARK, N.J., Nov. 01, 2021 (GLOBE... |
|
Oct 27 |
PDS Biotech Chief Medical Officer, Lauren V. Wood, to Present at the 2021 International Head and Neck Cancer Conference...
FLORHAM PARK, N.J., Oct. 27, 2021 (GLOBE... |
|
Oct 21 |
PDS Biotechnology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)...
FLORHAM PARK, N.J., Oct. 21, 2021 (GLOBE... |
|
Oct 21 |
PDS Biotech Provides Update on National Cancer Institute-Led Phase 2 Clinical Trial of PDS0101-Based Combination...
Temporary administrative suspension of... |
|
Oct 13 |
PDS Biotechnology Announces Conference Call and Webcast to Present Third-Quarter 2021 Financial Results...
FLORHAM PARK, N.J., Oct. 13, 2021 (GLOBE... |
|
Oct 06 |
PDS Biotechnology Welcomes Matthew Hill as Chief Financial Officer...
FLORHAM PARK, N.J., Oct. 06, 2021 (GLOBE... |
|
Oct 04 |
PDS Biotech Enrolls First Stage of Checkpoint Inhibitor Naïve Patient Arm of Phase 2 Clinical Trial in Advanced HPV-16 ...
FLORHAM PARK, N.J., Oct. 04, 2021 (GLOBE... |
|
Sep 27 |
PDS Biotechnology to Present at the Benzinga Healthcare Conference...
FLORHAM PARK, N.J., Sept. 27, 2021 (GLOBE... |
|
Sep 22 |
PDS Biotechnology to Present at the Cantor Fitzgerald Virtual Global Healthcare Conference...
FLORHAM PARK, N.J., Sept. 22, 2021 (GLOBE... |
|
Sep 20 |
PDS Biotech Achieves Safety Requirement Milestone For the First 12 Patients in the VERSATILE-002 Phase 2 Combination Tri...
No dose limiting toxicities observed in initial... |
|
Sep 15 |
PDS Biotech Reports An Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)...
FLORHAM PARK, N.J., Sept. 15, 2021 (GLOBE... |
|
Sep 13 |
PDS Biotechnology to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit ...
FLORHAM PARK, N.J., Sept. 13, 2021 (GLOBE... |
|
Sep 09 |
PDS Biotech Completes Enrollment of Lead-In Safety Cohort in VERSATILE-002 Phase 2 Combination Trial of PDS0101-KEYTRUDA...
FLORHAM PARK, N.J., Sept. 09, 2021 (GLOBE... |
|
Sep 07 |
PDS Biotechnology to Present at the HC Wainwright 23rd Annual Global Investment Conference...
FLORHAM PARK, N.J., Sept. 07, 2021 (GLOBE... |
|
Aug 12 |
PDS Biotech Provides Business Update and Reports Second Quarter 2021 Financial Results...
FLORHAM PARK, N.J., Aug. 12, 2021 (GLOBE... |
|
Jul 28 |
PDS Biotechnology to Present Recent Phase 2 Human Clinical Data and On-Going Oncology Programs at Investor Conferences...
FLORHAM PARK, N.J., July 28, 2021 (GLOBE... |
|
Jul 26 |
PDS Biotechnology Announces Conference Call and Webcast to Present Second Quarter 2021 Financial Results...
FLORHAM PARK, N.J., July 26, 2021 (GLOBE... |
|
Jul 01 |
PDS Biotechnology Joins Russell Microcap® Index...
FLORHAM PARK, N.J., July 01, 2021 (GLOBE... |
|
Jun 17 |
PDS Biotechnology Corporation Announces Closing of Approximately $52 Million Public Offering and Full Exercise of Underw...
FLORHAM PARK, N.J., June 17, 2021 (GLOBE... |
|
Jun 15 |
PDS Biotech Prices Public Offering of Common Stock...
FLORHAM PARK, N.J., June 15, 2021 (GLOBE... |
|
Jun 14 |
PDS Biotech Announces Proposed Offering of Common Stock...
FLORHAM PARK, N.J., June 14, 2021 (GLOBE... |
|
Jun 14 |
PDS Biotechnology Announces Oncology Research and Development Day...
FLORHAM PARK, N.J., June 14, 2021 (GLOBE... |
|
Jun 08 |
CORRECTING AND REPLACING -- PDS Biotech Announces Release of Interim Data for PDS0101 in NCI-Led Phase 2 Clinical Study ...
Tumor reduction was observed in 83% (5 of 6) of... |
|
Jun 08 |
PDS Biotech Announces Release of Interim Data for PDS0101 in NCI-Led Phase 2 Clinical Study in Oral Presentation at ASCO...
Tumor reduction was observed in 83% (5 of 6) of... |
|
Jun 07 |
PDS Biotechnology Set to Join Russell Microcap® Index...
FLORHAM PARK, N.J., June 07, 2021 (GLOBE... |
|
Jun 03 |
PDS Biotechnology Expands VERSATILE-002 study of PDS0101 and KEYTRUDA® in Advanced Head and Neck Cancer to Include Pati...
FLORHAM PARK, N.J., June 03, 2021 (GLOBE... |
|
Jun 01 |
PDS Biotech to Host Oncology R&D Day on June 16, 2021...
FLORHAM PARK, N.J., June 01, 2021 (GLOBE... |
|
May 27 |
PDS Biotechnology Establishes Partnership With Head and Neck Cancer Alliance...
Strategic partnership offers both organizations a way to... |
|
May 24 |
PDS Biotech to Host Company Conference Call Following Oral Presentation of PDS0101 Data at 2021 ASCO Annual Meeting...
FLORHAM PARK, N.J., May 24, 2021 (GLOBE... |
|
May 20 |
PDS Biotech Announces Release of Abstract for PDS0101 in NCI-Led Phase 2 Clinical Study for Oral Presentation at 2021 AS...
Objective responses (tumor reduction) observed in 83%... |
|
May 18 |
PDS Biotechnology Appoints Immuno-Oncology Experts Dr. Olivera Finn and Dr. Mark Frohlich to Scientific Advisory Board...
Preeminent translational cancer immunotherapy researcher... |
|
May 17 |
PDS Biotech Receives $4.5M After Selling Its Net Operating Loss Tax Benefits Through The New Jersey Economic Development...
FLORHAM PARK, N.J., May 17, 2021 (GLOBE... |
|
May 13 |
PDS Biotech Provides Business Update and Reports First Quarter 2021 Financial Results...
FLORHAM PARK, N.J., May 13, 2021 (GLOBE... |
|
May 12 |
PDS Biotechnology Announces Participation in Noble Capital Markets C-Suite Interview Series...
FLORHAM PARK, N.J., May 12, 2021 (GLOBE... |
|
Apr 29 |
PDS Biotech Announces Oral Presentation of PDS0101 Data by the National Cancer Institute at 2021 American Society of Cli...
FLORHAM PARK, N.J., April 29, 2021 (GLOBE... |
|
Apr 26 |
PDS Biotechnology Announces Conference Call and Webcast for First Quarter Financial Results...
FLORHAM PARK, N.J., April 26, 2021 (GLOBE... |
|
Apr 19 |
PDS Biotech Announces Participation in Noble Capital Markets Virtual Road Show Series...
Florham Park, NJ, April 19, 2021 (GLOBE... |
|
Mar 18 |
PDS Biotech Reports Financial Results for the Year Ended December 31, 2020 and Provides Business Update...
FLORHAM PARK, N.J., March 18, 2021 (GLOBE... |
|
Mar 17 |
PDS Biotech Announces Presentation and Panel Participation at the Benzinga Biotech Small Cap Conference...
Florham Park, NJ, March 17, 2021 - PDS... |
|
Mar 11 |
PDS Biotech Announces that its COVID-19 Vaccine Consortium Received a Commitment from The Ministry of Science, Technolog...
Development and commercialization of novel... |
|
Mar 08 |
PDS Biotechnology Announces Conference Call and Webcast for Fourth Quarter and Full Year 2020 Financial Results...
FLORHAM PARK, N.J., March 08, 2021 (GLOBE... |
|
Mar 03 |
PDS Biotech Announces Presentations in Upcoming Healthcare Investor Conferences...
FLORHAM PARK, N.J., March 03, 2021 (GLOBE... |
|
Feb 22 |
PDS Biotech and Farmacore Announce Blanver to Join Consortium to Commercialize Novel Versamune®-Based T-Cell Inducing C...
Brazilian-based Blanver brings depth of... |
|
Feb 03 |
PDS Biotech Announces Preliminary Efficacy Achievement in Phase 2 Combination Trial of PDS0101 Led by the National Cance...
Full enrollment triggered by observation of 3... |
|
Jan 14 |
PDS Biotech Releases White Paper Detailing the Potential of the Versamune® Platform in Overcoming a Major Limitation of...
Promotes in-vivo tumor-attacking killer T-cells to... |
|
Jan 06 |
PDS Biotechnology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)...
FLORHAM PARK, N.J., Jan. 06, 2021 (GLOBE... |
|
Jan 05 |
PDS Biotech Announces Participation in H.C. Wainwright BioConnect 2021 Virtual Conference...
FLORHAM PARK, N.J., Jan. 05, 2021 (GLOBE... |
